You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

19 Items
Cancer Type: Skin, Melanoma     
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
May 2019
Cancer Type: Hematologic, Lymphoma - T-cell, Rare Diseases     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
Sep 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate),
riTUXimab (Unfunded)
Dec 2017
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
Updated
Nov 2019
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Palliative
Drugs Used:
arsenic trioxide (Unfunded)
May 2019
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
New Drug Funding Program
    Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
May 2019
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
Funding:
New Drug Funding Program
    Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
Funding:
New Drug Funding Program
    Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Drugs Used:
temozolomide (Unfunded)
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Jun 2019
Cancer Type: Sarcoma, Ewing's     
Intent: Palliative
Drugs Used:
temozolomide (Unfunded),
Oct 2017
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria
Jun 2019